PTX-35 is a potential first-in-class agonistic monoclonal antibody targeting Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25, also known as DR3). By specifically activating the TNFRSF25 signaling pathway, the compound modulates T-cell immune responses, particularly within the tumor microenvironment. In experimental studies, PTX-35 has been demonstrated to reduce the suppressive activity of regulatory T cells (Tregs) and enhance CD4+ effector T-cell responses to tumor antigens, exhibiting significant anti-tumor potential.
Target:
TNF
* VAT and and shipping costs not included. Errors and price changes excepted
